

# Haitao Guo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5816032/publications.pdf>

Version: 2024-02-01

68  
papers

5,226  
citations

87888

38  
h-index

114465

63  
g-index

68  
all docs

68  
docs citations

68  
times ranked

5509  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interferon-Inducible Cholesterol-25-Hydroxylase Broadly Inhibits Viral Entry by Production of 25-Hydroxycholesterol. <i>Immunity</i> , 2013, 38, 92-105.	14.3	554
2	A global scientific strategy to cure hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 545-558.	8.1	342
3	Characterization of the Intracellular Deproteinized Relaxed Circular DNA of Hepatitis B Virus: an Intermediate of Covalently Closed Circular DNA Formation. <i>Journal of Virology</i> , 2007, 81, 12472-12484.	3.4	267
4	Identification of Three Interferon-Inducible Cellular Enzymes That Inhibit the Replication of Hepatitis C Virus. <i>Journal of Virology</i> , 2008, 82, 1665-1678.	3.4	255
5	Inhibition of Hepatitis B Virus Replication by the Host Zinc Finger Antiviral Protein. <i>PLoS Pathogens</i> , 2013, 9, e1003494.	4.7	204
6	Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4277-4288.	3.2	194
7	Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 32105-32113.	7.1	192
8	Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert!. <i>Journal of Medical Virology</i> , 2022, 94, 1255-1256.	5.0	169
9	Sulfamoylbenzamide Derivatives Inhibit the Assembly of Hepatitis B Virus Nucleocapsids. <i>Journal of Virology</i> , 2013, 87, 6931-6942.	3.4	154
10	Molecular Virology of Hepatitis B Virus for Clinicians. <i>Clinics in Liver Disease</i> , 2007, 11, 685-706.	2.1	151
11	Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 2066-2077.	7.3	150
12	Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection. <i>Hepatology</i> , 2019, 69, 1816-1827.	7.3	132
13	Regulation of Hepatitis B Virus Replication by the Phosphatidylinositol 3-Kinase-Akt Signal Transduction Pathway. <i>Journal of Virology</i> , 2007, 81, 10072-10080.	3.4	124
14	Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics. <i>Antiviral Research</i> , 2015, 122, 91-100.	4.1	122
15	Interferons Accelerate Decay of Replication-Competent Nucleocapsids of Hepatitis B Virus. <i>Journal of Virology</i> , 2010, 84, 9332-9340.	3.4	114
16	Production and Function of the Cytoplasmic Deproteinized Relaxed Circular DNA of Hepadnaviruses. <i>Journal of Virology</i> , 2010, 84, 387-396.	3.4	113
17	Chronic hepatitis B: What should be the goal for new therapies?. <i>Antiviral Research</i> , 2013, 98, 27-34.	4.1	112
18	Activation of Pattern Recognition Receptor-Mediated Innate Immunity Inhibits the Replication of Hepatitis B Virus in Human Hepatocyte-Derived Cells. <i>Journal of Virology</i> , 2009, 83, 847-858.	3.4	108

#	ARTICLE	IF	CITATIONS
19	A Southern Blot Assay for Detection of Hepatitis B Virus Covalently Closed Circular DNA from Cell Cultures. <i>Methods in Molecular Biology</i> , 2013, 1030, 151-161.	0.9	107
20	Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA. <i>PLoS Pathogens</i> , 2017, 13, e1006296.	4.7	107
21	Indoleamine 2,3-Dioxygenase Mediates the Antiviral Effect of Gamma Interferon against Hepatitis B Virus in Human Hepatocyte-Derived Cells. <i>Journal of Virology</i> , 2011, 85, 1048-1057.	3.4	106
22	Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential. <i>Antiviral Research</i> , 2020, 180, 104824.	4.1	92
23	Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. <i>Antiviral Research</i> , 2006, 72, 116-124.	4.1	86
24	The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation. <i>PLoS Pathogens</i> , 2017, 13, e1006784.	4.7	85
25	The Interferon-Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion. <i>Journal of Virology</i> , 2015, 89, 9200-9212.	3.4	84
26	Transcription of Hepatitis B Virus Covalently Closed Circular DNA Is Regulated by CpG Methylation during Chronic Infection. <i>PLoS ONE</i> , 2014, 9, e110442.	2.5	71
27	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018, 67, 1127-1131.	7.3	70
28	Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA. <i>Antiviral Research</i> , 2016, 134, 97-107.	4.1	63
29	Spinoculation Enhances HBV Infection in NTCP-Reconstituted Hepatocytes. <i>PLoS ONE</i> , 2015, 10, e0129889.	2.5	60
30	Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature $\epsilon$ -Mutation in Treated Chronic Hepatitis B Patients. <i>Hepatology</i> , 2021, 73, 41-52.	7.3	57
31	Identification and Characterization of Avihepadnaviruses Isolated from Exotic Anseriformes Maintained in Captivity. <i>Journal of Virology</i> , 2005, 79, 2729-2742.	3.4	54
32	Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection. <i>PLoS Pathogens</i> , 2019, 15, e1007690.	4.7	54
33	Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B. <i>Antiviral Research</i> , 2018, 158, 185-198.	4.1	53
34	Alkylated Porphyrins Have Broad Antiviral Activity against Hepadnaviruses, Flaviviruses, Filoviruses, and Arenaviruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 478-486.	3.2	52
35	Characterization of the Host Factors Required for Hepadnavirus Covalently Closed Circular (ccc) DNA Formation. <i>PLoS ONE</i> , 2012, 7, e43270.	2.5	49
36	Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	49

#	ARTICLE	IF	CITATIONS
37	Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBsAg for screening of cccDNA modulators. <i>Antiviral Research</i> , 2016, 132, 26-37.	4.1	48
38	Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues. <i>Scientific Reports</i> , 2015, 5, 10478.	3.3	41
39	Functional association of cellular microtubules with viral capsid assembly supports efficient hepatitis B virus replication. <i>Scientific Reports</i> , 2017, 7, 10620.	3.3	41
40	Hepatitis B Virus Precore Protein p22 Inhibits Alpha Interferon Signaling by Blocking STAT Nuclear Translocation. <i>Journal of Virology</i> , 2019, 93, .	3.4	38
41	Broad Severe Acute Respiratory Syndrome Coronavirus 2 Cell Tropism and Immunopathology in Lung Tissues From Fatal Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021, 223, 1842-1854.	4.0	33
42	Hepatitis B virus X protein crosses out Smc5/6 complex to maintain covalently closed circular DNA transcription. <i>Hepatology</i> , 2016, 64, 2246-2249.	7.3	27
43	Biogenesis and molecular characteristics of serum hepatitis B virus RNA. <i>PLoS Pathogens</i> , 2020, 16, e1008945.	4.7	27
44	SARS-CoV-2 pseudovirus infectivity and expression of viral entry-related factors ACE2, TMPRSS2, Kim1, and NRP1 in human cells from the respiratory, urinary, digestive, reproductive, and immune systems. <i>Journal of Medical Virology</i> , 2021, 93, 6671-6685.	5.0	26
45	A virus-like particle of the hepatitis B virus preS antigen elicits robust neutralizing antibodies and T cell responses in mice. <i>Antiviral Research</i> , 2018, 149, 48-57.	4.1	22
46	New Insights on Molecular Mechanism of Hepatitis B Virus Covalently Closed Circular DNA Formation. <i>Cells</i> , 2020, 9, 2430.	4.1	21
47	Detection of Hepatitis B Virus Particles Released from Cultured Cells by Particle Gel Assay. <i>Methods in Molecular Biology</i> , 2017, 1540, 193-202.	0.9	18
48	Characterization of the Termini of Cytoplasmic Hepatitis B Virus Deproteinized Relaxed Circular DNA. <i>Journal of Virology</i> , 2020, 95, .	3.4	16
49	Circulating HBV RNA: From biology to clinical applications. <i>Hepatology</i> , 2022, 76, 1520-1530.	7.3	15
50	The insertion domain of the duck hepatitis B virus core protein plays a role in nucleocapsid assembly. <i>Virology</i> , 2006, 353, 443-450.	2.4	13
51	Transforming growth factor $\beta$ -activated kinase 1 transcriptionally suppresses hepatitis B virus replication. <i>Scientific Reports</i> , 2017, 7, 39901.	3.3	12
52	Identification of Compounds Targeting Hepatitis B Virus Core Protein Dimerization through a Split Luciferase Complementation Assay. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	11
53	Detection of HBV cccDNA Methylation from Clinical Samples by Bisulfite Sequencing and Methylation-Specific PCR. <i>Methods in Molecular Biology</i> , 2017, 1540, 73-84.	0.9	10
54	RNA Helicase DDX17 Inhibits Hepatitis B Virus Replication by Blocking Viral Pregenomic RNA Encapsidation. <i>Journal of Virology</i> , 2021, 95, e0044421.	3.4	10

#	ARTICLE	IF	CITATIONS
55	Construction and characterization of two SARS-CoV-2 minigenome replicon systems. <i>Journal of Medical Virology</i> , 2022, 94, 2438-2452.	5.0	10
56	Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies. <i>Viruses</i> , 2021, 13, 1090.	3.3	7
57	Proteomic Analysis of Nuclear Hepatitis B Virus Relaxed Circular DNA-Associated Proteins Identifies UV-Damaged DNA Binding Protein as a Host Factor Involved in Covalently Closed Circular DNA Formation. <i>Journal of Virology</i> , 2022, 96, JVI0136021.	3.4	7
58	Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine-resistant HBV isolate. <i>Antiviral Research</i> , 2019, 165, 47-54.	4.1	5
59	Hepatitis B virus X protein counteracts high mobility group box 1 protein-mediated epigenetic silencing of covalently closed circular DNA. <i>PLoS Pathogens</i> , 2022, 18, e1010576.	4.7	4
60	Elevated NTCP expression by an iPSC-derived human hepatocyte maintenance medium enhances HBV infection in NTCP-reconstituted HepG2 cells. <i>Cell and Bioscience</i> , 2021, 11, 123.	4.8	3
61	Fluorescent protein tagged hepatitis B virus capsid protein with long glycine-serine linker that supports nucleocapsid formation. <i>Journal of Virological Methods</i> , 2018, 255, 52-59.	2.1	2
62	Intrahepatic transcriptomics reveals gene signatures in chronic hepatitis B patients responded to interferon therapy. <i>Emerging Microbes and Infections</i> , 2022, 11, 1876-1889.	6.5	2
63	A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation. <i>Antiviral Research</i> , 2016, 126, 99-107.	4.1	1
64	A novel phenotypic assay of hepatitis B virus polymerase with extensive site-specific mutagenesis. <i>Virologica Sinica</i> , 2017, 32, 167-170.	3.0	0
65	The butterfly effect in viral infection: From a host DNA single nucleotide change to HBV episome steadiness. <i>Genes and Diseases</i> , 2019, 6, 3-5.	3.4	0
66	Strategies to improve the fluorescent signal of the tripartite sfGFP system. <i>Acta Biochimica Et Biophysica Sinica</i> , 2020, 52, 998-1006.	2.0	0
67	REPLY:. <i>Hepatology</i> , 2021, 73, 2076-2077.	7.3	0
68	Letter to the Editor: Can the Ratio of Serum HBV RNA to DNA Reflect the Reverse-Transcription Efficiency of Viral pgRNA?. <i>Hepatology</i> , 2021, 74, 532-533.	7.3	0